MetaCap

Caribou Biosciences Inc. (CRBU)

NASDAQ: CRBUHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.2843-0.0262 (-8.44%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CRBU stock chart

Technical analysis

Key statistics

All statistics
Market cap
$30.71M
EPS (TTM)
-$1.03
52-week range
0.2819 – 2.49
Day range
0.2819 – 0.3051
Volume / Avg
3.26M / 2.87M
Beta
—

52-week range

$0.2819$2.49

CRBU stock today

On Nov 20, CRBU ended the session at $0.2843, shedding $0.0262 (8.44%), versus the S&P 500's 3.70% decline. At this level, CRBU sits near the bottom of its 52-week range of $0.2819 to $2.49: 88.6% below the high, set on Jun 1, 2026 and 0.9% above the low. CRBU is down 82.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 83.8%.

Caribou Biosciences has posted a net loss over the last twelve months (EPS of -$1.03), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Caribou Biosciences

Company profile

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Rachel E. Haurwitz Ph.D.
Headquarters
Berkeley, CA
Employees
97
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Caribou Biosciences generated $11.2 million in revenue, up 11.7% from fiscal 2024. Caribou Biosciences reported a net loss of $148.1 million, compared with a loss of $149.1 million a year earlier. Operating margin was -1329.4%.

Caribou Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$11.16M$9.99M$34.48M$13.85M$9.60M
Growth+11.66%-71.01%+148.91%+44.31%-22.35%
Net income$-148.13M$-149.10M$-102.07M$-99.42M$-66.92M
EPS (diluted)$-1.59$-1.65$-1.38$-1.64$-2.11

Analyst forecast

Forecast

Consensus (6 analysts)

buy

Avg. price target

$5.75+1922.51%

  • Strong buy 0
  • Buy 2
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $1.00High $13.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.25 vs $-0.27
Surprise
+7.41%

CRBU news

All CRBU news

Caribou Biosciences peers

Health Care sector
CRBU peer companies
CompanyPrice% ChgMarket capCompare
KLRSKalaris Therapeutics Inc.1.28-5.19%$30.47Mvs CRBU
EXOZeXoZymes Inc.2.91-14.05%$27.42Mvs CRBU
LONALeonaBio Inc.2.02-17.89%$26.41Mvs CRBU
TILInstil Bio Inc.5.23-5.77%$35.47Mvs CRBU
INMBINmune Bio Inc.0.827-7.50%$25.60Mvs CRBU
PTHSPelthos Therapeutics Inc.6.38-8.73%$25.08Mvs CRBU
SAENGenenta Science S.p.A. ADR0.5074-9.39%$24.47Mvs CRBU
ELUTElutia Inc. Class A0.9001+11.12%$39.96Mvs CRBU

Indexes, lists and sector

Caribou Biosciences stock FAQ

What is Caribou Biosciences's stock price today?

CRBU last traded at $0.2843 as of Nov 20, 4:00 PM EST, down 8.44% on the day. Prices are delayed at least 15 minutes.

Who is Caribou Biosciences's CEO?

Dr. Rachel E. Haurwitz Ph.D. is the chief executive officer of Caribou Biosciences Inc., which has about 97 employees.

What is the CRBU 52-week high?

The 52-week high for CRBU is $2.49 and the 52-week low is $0.2819. The stock is currently 88.6% below its high.

Compare CRBU